Randomized Phase Ii Study Of Nivolumab (N) Alone Versus With Pegilodecakin (Peg) In Combination With N In Patients (Pts) With Post-Platinum Immunotherapy-Naive Stage Iv Non-Small Cell Lung Cancer (Nsclc) And No Or Low Pd-L1 Expression (Cypress 2).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要